Approval · Notice of Compliance 19625 · 2017
BOSULIF: Notice of Compliance 19625
Issued August 3, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 19625
- Date
- August 3, 2017
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Fulfilment of the Post-Approval Commitments for the Notice of Compliance with conditions for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BOSULIF | Not yet assigned | — |